Segment Information (Tables)

6 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Segment Information [Text Block]

	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2013			2012		2013			2012
Segment revenue — to unaffiliated customers:
Human pharmaceutical products:
Neuroscience	$	2,004.5		$	1,824.5	$	3,853.4		$	3,728.2
Endocrinology	1,784.3			1,704.1		3,509.2			3,395.1
Oncology	808.1			846.8		1,572.3			1,650.6
Cardiovascular	731.3			646.9		1,425.3			1,284.9
Other pharmaceuticals	58.0			66.2		129.1			140.9
Total human pharmaceutical products	5,386.2			5,088.5		10,489.3			10,199.7
Animal health	543.5			512.2		1,042.4			1,003.0
Total segment revenue	$	5,929.7		$	5,600.7	$	11,531.7		$	11,202.7
Segment profits:
Human pharmaceutical products	$	1,430.7		$	1,049.3	$	2,778.8		$	2,280.9
Animal health	147.7			136.4		277.0			263.9
Total segment profits	$	1,578.4		$	1,185.7	$	3,055.8		$	2,544.8
Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	1,578.4		$	1,185.7	$	3,055.8		$	2,544.8
Other profits (losses):
Income related to transfer of exenatide commercial rights (Note 4)	—			—		495.4			—
Asset impairments, restructuring, and other special charges (Note 5)	(63.5		)	—		(85.2		)	(23.8		)
Total consolidated income before taxes	$	1,514.9		$	1,185.7	$	3,466.0		$	2,521.0